Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1622-1636
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1622
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1622
Table 2 Overall survival of patients with hepatocellular carcinoma receiving first-line immunotherapy alone or in combination, based on the etiology of the liver disease
| Treatment | HCC etiology | HR (95%CI) | Trial | Phase |
| Atezolizumab plus bevacizumab vs sorafenib in first-line | Nonviral HCC | 1.05 (0.68-1.63) | IMbrave150[93] | III |
| HBV-HCC | 0.58 (0.40-0.83) | |||
| HCV-HCC | 0.43 (0.25-0.73) | |||
| Nivolumab vs sorafenib in first-line | Nonviral HCC | 0.91 (0.72-1.16) | CheckMate-459[86] | III |
| HBV-HCC | 0.79 (0.59-1.07) | |||
| HCV-HCC | 0.72 (CI 0.51-1.02) | |||
| Atezolizumab plus cabozantinib vs sorafenib in first-line | Nonviral HCC | 1.18 (0.78–1.79) | COSMIC-312[99] | III |
| HBV-HCC | 0.53 (0.33-0.87) | |||
| HCV-HCC | 1.10 (0.72-1.68) | |||
| Tremelimumab 300 mg × 1 dose + Durvalumab 1500 mg vs sorafenib in first-line | Nonviral HCC | 0.74 (0.57-0.95) | HIMALAYA[89] | III |
| HBV-HCC | 0.64 (0.48-0.86) | |||
| HCV-HCC | 1.06 (0.76-1.49) |
- Citation: Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1622.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1622